{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-003188","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.072367+00:00","generated_at":"2026-06-15T04:48:41.395875+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MiNK Therapeutics Q1 net loss $5.7M; agenT-797 shows durable responses in solid tumors","bullets":["Net loss $5.7M ($0.17/share) vs $7.8M ($0.23) in Q1 2022; cash $14.9M at March 31, 2023.","agenT-797 + anti-PD-1 achieved 42% tumor reduction in metastatic gastric cancer lasting >9 months; durable disease stabilization in anti-PD-1 refractory NSCLC.","Initiating phase 1/2 expansion studies in NSCLC and gastric cancer; majority costs planned for external non-dilutive grant funding.","Upcoming presentations: FAP-CAR-iNKT at ASGCT May 19; agenT-797 in viral ARDS at ATS May 21.","Manufacturing capacity 5,000 doses/year, rapidly expanding."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-003188","json":"https://secwatch.observer/filing/0001171843-23-003188.json","markdown":"https://secwatch.observer/filing/0001171843-23-003188.md","text":"https://secwatch.observer/filing/0001171843-23-003188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000117184323003188/0001171843-23-003188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000117184323003188/f8k_051123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:48:41.395875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29e51842184716dc9f29595b21e262019265258f","claim":"MiNK Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income $5.7 million or $0.17 per share, EPS $0.17 per share.","evidence_excerpt":"Net loss for the quarter ended March 31, 2023, was $5.7 million or $0.17 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840229/000117184323003188/0001171843-23-003188-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"$5.7 million or $0.17 per share"},{"label":"EPS","value":"$0.17 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}